Glucagon like Peptide 1 News and Research

RSS

Simple blood test could identify the most effective obesity drug

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, enhancing personalized therapy.

29 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Early diabetes drug treatment links to better survival after diagnosis thresholds

A Korean target trial emulation found that starting antidiabetic medication within 12 months of newly crossing type 2 diabetes diagnostic thresholds was associated with lower five-year all-cause mortality. MACE risk was numerically lower with earlier treatment, but the reductions in cardiovascular events were not statistically significant, underscoring the need for larger studies.

24 Jun 2026

Researchers trace soaring poison control calls to semaglutide approval for weight loss

When semaglutide's popularity exploded following FDA approval for weight management in 2021, so too did a wave of calls to poison control centers.

23 Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

18 Jun 2026

Gut microbes may help explain why obesity and type 2 diabetes become harder to reverse

This review describes how gut microbial messengers, including SCFAs, microbiota-modified bile acids, neuroactive metabolites, and extracellular vesicles, may shape obesity and type 2 diabetes through the microbiota-gut-brain axis.

17 Jun 2026

Weight-loss medications lessen the risk of violent criminal behavior

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain's reward and stress systems.

17 Jun 2026

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug.

16 Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

GLP-1 users say the drugs quiet food noise but do not replace lifestyle change

A qualitative study of 30 US adults found that GLP-1 receptor agonists often reduced “food noise,” psychological hunger, and appetite, helping patients feel more able to make deliberate lifestyle changes.

8 Jun 2026

GLP-1 therapies linked to fewer complications in adults with both obesity and autoimmune disease

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

7 Jun 2026

Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies

EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.

4 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026

GLP-1 therapy linked to slower biological aging processes

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease.

2 Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

1 Jun 2026